Gland Pharma Q4 Results
- BSE: 543245
- NSE: GLAND
- ISIN: INE068V01023
- Sector: Biotechnology & Drugs
BSE
2,455
-78.00 (-3.08%)
-78.00 (-3.08%)Volume8.95 K
Updated: Fri 17 Jul, 2026 | 10:53:11
NSE
2,454.80-74.60 (-2.95%)
-74.60 (-2.95%)Volume1.04 L
Updated: Fri 17 Jul, 2026 | 10:38:22
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
- Total Income₹1,742.79 Cr.(22.31%)
- Operating Profit₹404.36 Cr.(60.62%)
- Profit After Tax₹366.68 Cr.(96.57%)
- Operating Margin23.20%(31.32%)
Note: Comparison is on YoY basis
Quarterly - Gland Pharma Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 26 | Dec 25 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 1,338.43 | 1,392.48 | -3.88% | 1,271.41 | 14.09% |
| Depreciation/ Amortization | 108.66 | 107.65 | 0.94% | 92.61 | 13.47% |
| Operating Income | 404.36 | 302.89 | 33.50% | 266.04 | 60.62% |
| Net Income | 366.68 | 261.48 | 40.23% | 192.42 | 96.57% |
| Other Operating Expenses Total | 173.85 | 205.63 | -15.46% | 169.93 | 6.35% |
| Net Income Before Taxes | 505.80 | 362.13 | 39.67% | 298.23 | 75.42% |
| Total Revenue | 1,742.79 | 1,695.36 | 2.80% | 1,537.45 | 22.31% |
| Selling/ General/ Admin Expenses Total | 411.57 | 424.20 | -2.98% | 409.49 | 10.23% |
| Diluted Normalized EPS | 22.23 | 16.94 | 31.25% | 11.67 | 96.38% |
EQUITY QUICK LINKS
FROM MARKETS
Trending Stocks
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.